FibroGen's Q1 results show a loss, but a high return on invested capital (ROIC) of 155.76% indicates effective capital allocation. This suggests that the company is operating efficiently and may achieve favorable long-term returns. However, the short-term impact on the stock price is uncertain, as ROIC is not a highly reliable predictor of near-future earnings or sales.